Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

93.19
+3.263.63%
Post-market: 93.190.00000.00%19:30 EDT
Volume:1.24M
Turnover:114.72M
Market Cap:8.22B
PE:-46.36
High:95.27
Open:91.16
Low:90.48
Close:89.93
52wk High:110.18
52wk Low:15.86
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.96
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.61
PE(LYR):-47.17

Loading ...

Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

GlobeNewswire
·
Aug 26

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.
·
Aug 20

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 15

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

TIPRANKS
·
Aug 13

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Aug 11

Spyre Therapeutics Director Jeffrey W. Albers Disposes of USD 2.39 Million in Common Shares

Reuters
·
Aug 11

Spyre Therapeutics Launches Program, Mid-Stage Trial for Drug Combination to Treat Hidradenitis Suppurativa

MT Newswires Live
·
Aug 10

Spyre Therapeutics Announces Launch of Spy772 Program and Initiation of Phase 2 Skylight Trial in Hidradenitis Suppurativa

THOMSON REUTERS
·
Aug 10

Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa

GlobeNewswire
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Spyre Therapeutics (SYRE), Revolution Medicines (RVMD)

TIPRANKS
·
Aug 08

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Aug 08

Spyre Therapeutics CEO Turtle Cameron Sells Common Shares Worth $1.42 Million

Reuters
·
Aug 06

Spyre Therapeutics Inc : Jefferies Raises Target Price to $122 from $98

THOMSON REUTERS
·
Aug 05

Spyre Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Spyre Therapeutics Q2 Loss Narrower than Expected; Sees Trial Readouts in 2026

Reuters
·
Aug 05

Press Release: Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 05

Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim

TIPRANKS
·
Jul 25